[18F]-fluorodeoxyglucose - Positron emission tomography in patients with active myelopathy

Mayo Clinic Proceedings

Volumn 88, Issue 11, 2013, Pages 1204-1212

  Flanagan, Eoin P ^a   Hunt, Christopher H ^a   Lowe, Val ^a   Mandrekar, Jay ^a   Pittock, Sean J ^a   O'Neill, Brian Patrick ^a   Keegan, B Mark ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CEREBROSPINAL FLUID; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DEMYELINATING DISEASE; FEMALE; HUMAN; LEUKEMIA; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; METABOLISM; MYELITIS; NEUROIMAGING; NEUROSARCOID MYELOPATHY; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIMARY TUMOR; RETROSPECTIVE STUDY; SARCOIDOSIS; SPINAL CORD DISEASE; SPINAL CORD METABOLISM; SPINAL CORD METASTASIS; SPINAL CORD TUMOR;

EID: 84888876901     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2013.07.019     Document Type: Article

References (28)

1. Cohen-Gadol AA, Zikel OM, Miller GM, Aksamit AJ, Scheithauer BW, Krauss WE. Spinal cord biopsy: a review of 38 cases. Neurosurgery. 2003;52(4):806-815; discussion 815-806.
2. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006;354(5): 496-507.
3. Iacoboni M, Baron JC, Frackowiak RS, Mazziotta JC, Lenzi GL. Emission tomography contribution to clinical neurology. Clin Neurophysiol. 1999;110(1):2-23.
4. Ota K, Tsunemi T, Saito K, et al. 18F-FDG PET successfully detects spinal cord sarcoidosis. J Neurol. 2009;256(11):1943-1946.
5. Sakushima K, Yabe I, Shiga T, et al. FDG-PET SUV can distinguish between spinal sarcoidosis and myelopathy with canal stenosis. J Neurol. 2011;258(2):227-230.
6. Chamroonrat W, Posteraro A, El-Haddad G, Zhuang H, Alavi A. Radiation myelopathy visualized as increased FDG uptake on positron emission tomography. Clin Nucl Med. 2005; 30(8):560.
7. Flanagan EP, O'Neill BP, Habermann TM, Porter AB, Keegan BM. Secondary intramedullary spinal cord non-Hodgkin's lymphoma. J Neurooncol. 2012;107(3):575-580.
8. Flanagan EP, O'Neill BP, Porter AB, Lanzino G, Haberman TM, Keegan BM. Primary intramedullary spinal cord lymphoma. Neurology. 2011;77(8):784-791.
9. Karantanis D, O'Eill BP, Subramaniam RM, et al. 18F-FDG PET/ CT in primary central nervous system lymphoma in HIVnegative patients. Nucl Med Commun. 2007;28(11):834-841.
10. Jayasundera MV, Thompson JF, Fulham MJ. Intramedullary spinal cord metastasis from carcinoma of the lung: detection by positron emission tomography. Eur J Cancer. 1997;33(3):508-509.
11. Wilmshurst JM, Barrington SF, Pritchard D, et al. Positron emission tomography in imaging spinal cord tumors. J Child Neurol. 2000;15(7):465-472.
12. Graus F, Delattre JY, Antoine JC, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8):1135-1140.
13. Transverse Myelitis Consortium Working Group. Proposed diagnostic criteria and nosology of acute transverse myelitis. Neurology. 2002;59(4):499-505.
14. Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006;66(10):1485-1489.
15. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302.
16. Schiff D,O'Neill BP. Intramedullary spinal cord metastases: clinical features and treatment outcome. Neurology. 1996;47(4):906-912.
17. Flanagan EP, McKeon A, Lennon VA, et al. Paraneoplastic isolated myelopathy: clinical course and neuroimaging clues. Neurology. 2011;76(24):2089-2095.
18. Keegan BM, Pittock SJ, Lennon VA. Autoimmune myelopathy associated with collapsin response-mediator protein-5 immunoglobulin G. Ann Neurol. 2008;63(4):531-534.
19. Ashawesh K, Abdulqawi R, Ahmad S. Syrinx associated with an intramedullary metastasis. Intern Med. 2008;47(4):329-330.
20. Stern BJ, Aksamit A, Clifford D, Scott TF; Neurosarcoidosis Study Group. Neurologic presentations of sarcoidosis. Neurol Clin. 2010;28(1):185-198.
21. Di Chiro G, Oldfield E, Bairamian D, et al. Metabolic imaging of the brain stem and spinal cord: studies with positron emission tomography using 18F-2-deoxyglucose in normal and pathological cases. J Comput Assist Tomogr. 1983;7(6):937-945.
22. Do BH, Mari C, Tseng JR, Quon A, Rosenberg J, Biswal S. Pattern of 18F-FDG uptake in the spinal cord in patients with non-central nervous system malignancy. Spine (Phila Pa 1976). 2011;36(21):E1395-E1401.
23. Salamon N, Kung J, Shaw SJ, et al. FDG-PET/MRI coregistration improves detection of cortical dysplasia in patients with epilepsy. Neurology. 2008;71(20):1594-1601.
24. Poggi MM, Patronas N, Buttman JA, Hewitt SM, Fuller B. Intramedullary spinal cord metastasis from renal cell carcinoma: detection by positron emission tomography. Clin Nucl Med. 2001;26(10):837-839.
25. Jain A, Jalali R, Nadkarni TD, Sharma S. Primary intramedullary primitive neuroectodermal tumor of the cervical spinal cord: case report. J Neurosurg Spine. 2006;4(6):497-502.
26. Komori T, Delbeke D. Leptomeningeal carcinomatosis and intramedullary spinal cord metastases from lung cancer: detection with FDG positron emission tomography. Clin Nucl Med. 2001;26(11):905-907.
27. Knight SB, Delbeke D, Stewart JR, Sandler MP. Evaluation of pulmonary lesions with FDG-PET: comparison of findings in patients with and without a history of prior malignancy. Chest. 1996;109(4):982-988.
28. Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood. 2007;110(10):3507-3516.